Edit
Pulse Therapeutics, Inc.
http://www.pulsetherapeutics.com/Last activity: 05.03.2014
Active - Reference to Euphrates Vascular
Pulse Therapeutics provides a technology to combat blood clots using the power of magnets. Pulse’s signature offering, the MED System, was designed to harness magnet-based technology to rapidly dissolve blood clots faster than current modalities.
Location: United States, Illinois, St. Louis
Employees: 1-10
Phone: +1 314-241-5579
Founded date: 2008
Investors 3
Mentions in press and media 5
| Date | Title | Description |
| 05.03.2014 | A magnet-based approach to optimizing stroke treatment snags $1.3M from St. Louis investors | There’s an FDA-approved treatment for ischemic strokes, but it comes with some baggage. The issue is that tPA, a thrombolytic agent that dissolves clots and restores blood flow to the brain, is supposed to be administered within three to fo... |
| 31.01.2012 | Magnet technology to destroy blood clots in stroke attracts $3.1M in funding | Earlier this year, the company closed a $1.65 million series A round led by BioGenerator, a St. Louis nonprofit life sciences group. It also won a $50,000 first-place prize from the 2011 St. Louis Regional Business Plan Competition last sum... |
| 12.08.2010 | Pulse Therapeutics Raises Early-Stage Funding | Pulse Therapeutics, Inc., a St. Louis, MO-based company that develops innovative magnetism-based technology to safely destroy blood clots related to ischemic stroke and deep vein thrombosis (DVT), has raised an early-stage funding of undisc... |
| - | A magnet-based approach to optimizing stroke treatment snags $1.3M from St. Louis investors | Pulse Therapeutics just scored a $1.3 million investment in a push toward clinical trials for technology that may be able to deliver drug treatments for stroke to the brain quicker. The capital for St. Louis-based Pulse came from local firm... |
| - | Magnet technology to destroy blood clots in stroke attracts $3.1M in funding | A new, magnet-based technology to destroy blood clots could improve the standard of care for ischemic stroke and deep vein thrombosis, says a St. Louis, Missouri medical device startup. Pulse Therapeutics closed in on $3.1 million late last... |